Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.86 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.72 |
| ▸ | PRKCG | P05129 | 3/20 | 0.72 |
| ▸ | PRKCB | P05771 | 3/20 | 0.72 |
| ▸ | PRKCA | P17252 | 3/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.72 |
| ▸ | PRKCH | P24723 | 3/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.72 |
| ▸ | PRKCI | P41743 | 3/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.72 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.72 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3733547 | 1.00 | CHEK1 (0.86) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3733543 | 1.00 | CHEK1 (0.86) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3381807 | 0.93 | CHEK1 (1.00) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3382255 | 0.93 | CHEK1 (1.00) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3381730 | 0.93 | CHEK1 (1.00) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL14796246 | 0.86 | CHEK1 (0.77) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL14796040 | 0.86 | CHEK1 (0.77) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL14796445 | 0.86 | CHEK1 (0.77) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3841380 | 0.86 | CHEK1 (0.77) | CHEK1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3843161 | 0.86 | CHEK1 (0.79) | CHEK1PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | CHEK1 1/4885PRKD3 457/4885PRKCG 611/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | CHEK1 2063/4885PRKD3 1017/4885PRKCG 2188/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CHEK1 2358/4885PRKD3 3788/4885PRKCG 3175/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | CHEK1 154/4885PRKD3 3369/4885PRKCG 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.